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Adviser: Jayne Stratton
Probiotics, live microorganisms that beneficially affect the health of their host, must
undergo extensive research to ensure they are safe for consumption and possess certain
functional properties. Antibiotic resistance in probiotics has raised concern due to the
possibility of its transfer to pathogens. Acid and bile tolerance ensures that organisms
will survive passage into the intestines. Prebiotic utilization indicates ability to ferment
specific carbohydrates for enhanced growth.

The objective of this study was to

characterize a group of commercial probiotics for their suitability as probiotics.
Nine commercial probiotic strains (7 Lactobacillus, 1 Lactococcus lactis, and 1
Bifidobacterium longum) were evaluated. Two methods, disk diffusion and broth
microdilution, were utilized to determine susceptibility to 9 antibiotics (ampicillin,
chloramphenicol, clindamycin, erythromycin, gentamycin, kanamycin, oxytetracycline,
streptomycin, and vancomycin). Most strains were susceptible to 4 or more antibiotics.
Only one strain, Lactobacillus salivarius, showed resistance to three antibiotics. The two
methods tested were in agreement for 76.8% (63/82) of the bacteria-antibiotic
combinations tested.
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The

cultures

were

assessed

for

their

ability

to

utilize

four

prebiotics:

galactooligosaccharides (GOS), two fructooligosaccharide (FOS), and inulin. Glucose
was used as a positive control for growth. Galactooligosaccharides were fermented by
seven strains and fructooligosaccharides derived from chicory, by two strains. Inulin did
not promote significant growth of any of the strains.
Additionally, Bacillus coagulans ProDura is a sporeforming bacterium that has recently
been identified and marketed as a novel probiotic with a greater ability to survive the low
pH of the stomach when in spore form. This organism showed high tolerance to acid and
bile conditions, with only a two log reduction after four hours at pH 2.0, and only a one
log reduction in bile salts. It was susceptible to all antibiotics tested and was able to
utilize GOS and FOS, but not inulin. In conclusion, the strains evaluated comply with the
functional and safety characteristics of probiotics, except for the strain of Lactobacillus
salivarius which demonstrated an unacceptable level of antibiotic resistance.
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CHAPTER 1 : LITERATURE REVIEW

2

1.1. Lactic acid bacteria
Lactic acid bacteria (LAB) are a group of Gram-positive bacteria that excrete lactic acid
as their main fermentation product (1). Typical LAB members are Gram-positive,
facultative anaerobic, catalase-negative organisms with low G+C content, of the genera
Lactobacillus, Lactococcus, Leuconostoc and Pediococcus. Though the genera
Propionobacterium and Bifidobacterium belong to the high G+C branch, they have been
grouped with the LAB for practical and ecological reasons (2).

Most LAB have a long history of being consumed as part of traditional fermented foods
and have been awarded the status of “Generally Regarded As Safe” (GRAS) by the Food
and Drug Administration (FDA) (2). Lactobacilli are naturally present or deliberately
added as starter cultures in unpasteurized milk and dairy products such as cheeses,
yogurts and fermented milks (3). Leuconostoc, Lactobacillus and Pediococcus species are
commonly established in plant material and are essential for the manufacture of
fermented vegetable products (e.g. miso, soy sauce, pickled vegetables and kimchi) (4).
LAB starters are also used in dry sausage, where they affect the texture, flavor, shelf-life
and safety of the product (5).

1.2. Probiotics
Probiotics are defined as cultures of living microorganisms which beneficially affect the
health of the host when administered in adequate amounts (2). These microorganisms
survive passage through the gastrointestinal tract and eventually establish in the colon.
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However, they must be taken regularly and at sufficiently high levels to avoid washout
and to ensure sustained benefits (4). Their benefits are related to the prevention of growth
of harmful bacteria by competitive exclusion and by the production of organic
compounds (5). Associated effects of probiotics include prevention and treatment of
diarrhea, alleviation of lactose intolerance, immunomodulation and prevention or
alleviation of allergies in children (4, 5).

Global sales of probiotic products reached US$21.6 billion in 2010 and US$24.23 billion
in 2011 (6). The global probiotic market is expected to reach US$44.9 billion in 2018 (6).
Asia-Pacific is currently the largest probiotic market and is likely to remain the market
leader; however, European and North American markets continue to grow (6). In the
United States, probiotics are available primarily as capsules or sachet preparations,
although food formats are increasing. Unlike Canada and some European countries, the
United States has no governmental standards for probiotics, which leads to variable
products that do not contain the bacteria or the number of bacteria stated in the product’s
label (7). Consumer education and clearer regulations are needed for the probiotic market
to reach its full potential in the United States.

1.3. Bacterial species used as probiotics
Lactic acid bacteria are normal residents of the human gastrointestinal tract, especially in
the colon, where their numbers can be up to 9 log CFU/g (5). The two genera most
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commonly used as probiotics are Lactobacillus and Bifidobacterium. Neither genera
includes any significant pathogenic species (8).

In healthy humans, lactobacilli are normally present in the oral cavity (103-104 CFU/g),
the ileum (103-107 CFU/g), and the colon (104-108 CFU/g) (9). They are also widely
found in raw milk and fermented dairy products, which continue to be the preferred way
to market probiotic strains in food products in the United States (7). Beneficial effects of
lactobacilli include control of intestinal inflammation, treatment of infections during
pregnancy, management of allergic diseases, control of antibiotic-related diarrhea and
prevention of urinary tract infections, amongst others (9).

Bifidobacterium are not considered true LAB, given their high G+C content and their
production of a combination of lactic and acetic acid. However, they are normal
inhabitants of the gastrointestinal tract of humans, making up to 25% of the cultivable
fecal bacteria in adults and 80% in infants (8). They are commonly used as probiotics,
with a long history of safe use in fermented dairy products. Their positive effects on
human health include prevention of infection by pathogenic bacteria, immunostimulatory
and anti-carcinogenic capabilities, protection against infectious diarrhea, lowering of
serum cholesterol and alleviation of lactose intolerance (10).
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Spore forming bacteria, such as Bacillus coagulans, Bacillus racemilacticus and Bacillus
laevolacticus, have only recently received attention as potential probiotics. However,
many factors make them good candidates for probiotic use, such as the ease of culturing
them in bulk, their production of organic acids and their capacity to sporulate (11).
Spores are hardy dormant life forms. One of their most important traits is that they are
heat stable, so they can be included in products stored at room temperature without losing
viability (12). Both in vitro and mouse model experiments have shown that Bacillus
coagulans spores are capable of germinating in the small intestine, where they could
arguably have a beneficial effect (13, 14). Certain strains of Bacillus coagulans are
capable of producing a bacteriocin-like inhibitory substance, coagulin, which has shown
in vitro activity against Enterococcus and Listeria (15). Mice studies have shown
Bacillus coagulans consumption improves some indices of Clostridium difficile-induced
colitis (16). Human trials suggest a certain strain of this species may have positive effects
on functional intestinal gas symptoms and rheumatoid arthritis symptoms (17, 18).
However, there are still very few human studies on the effects of Bacillus probiotics for
them to achieve the same level of acceptance as lactobacilli and Bifidobacterium
probiotics.

1.4. Properties of probiotics
The Food and Agriculture Organization (FAO) and the World Health Organization
(WHO) released a joint report in 2002 for the evaluation of probiotics. To be classified as
probiotics, strains must be identified by phenotypic and genotypic methods, since many
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probiotic effects are strain-specific. Then, they should go through a functional
characterization and a safety assessment, both in vitro and with animal studies, before
being tested for efficacy in a double blind, randomized, placebo-controlled human trial
(19). A second independent trial is preferred before the strain can be considered a
probiotic and be added to food products.

1.4.1. Functional properties of probiotics
The beneficial effects of probiotics depend on their colonization of the gut and their
effect on harmful bacteria, for which certain functional properties are necessary.
Probiotics must survive gastric and bile acids in order to reach the intestinal tract (11).
Once there, they must be capable of adhering to human epithelial cells. Lastly, they
should prevent colonization by pathogenic bacteria, either by immune exclusion,
competitive adhesion or synthesis of antimicrobial substances (13, 19).

1.4.1.1.

Acid and bile resistance

Probiotic strain selection can start with screening for acid and bile resistance. The pH of
excreted hydrochloric acid in the stomach is 0.9. However, the presence of food raises the
pH value to around pH 3 (5). The ability to survive and grow in a low pH environment is
characteristic of LAB, although their tolerance mechanism is not clarified yet. (20) Bile
salts, on the other hand, are released into the small intestine after ingestion of fatty foods.
They have a detergent-like function, which may disrupt the lipids and fatty acids of
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bacterial cell membranes (21). Certain microorganisms, including several species of
Lactobacillus, can reduce this detergent effect by hydrolyzing bile salts with the bile salt
hydrolase (BSH) enzyme (5, 20).

In vivo methods are available for investigating the survival of probiotic bacteria in the
human gut. As these methods are expensive, laborious and pose ethical constraints, in
vitro methods are preferred for the first selection of strains (14). In these in vitro
methods, cultures are usually exposed to acid conditions (pH 2 to 3) or bile presence
(0.3% w/v) in broth for up to four hours. Growth or survival is then monitored (21).

Bacillus species generate dormant spores resistant to heat, desiccation, enzymatic
degradation and acidic conditions (22). This increases their potential as probiotics for
human or animal use. In vitro experiments have shown that spores from different strains
of Bacillus coagulans, Bacillus laevolacticus and Sporolactobacillus are able to tolerate
pH conditions as low as 2.0 to a varying degree, according to strain and environment
conditions (11, 14, 22–24). Similar tests have been performed for bile resistance, with
only a slight loss of viability for most strains of Bacillus tested (11, 14, 22). Germination
of Bacillus subtilis spores in the intestine of mice has been reported (25), which is
necessary as only the vegetative cells are able to have a probiotic effect.
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1.4.1.2.

Prebiotic utilization

Prebiotics are defined as non-digestible food ingredients that beneficially affect the host
by selectively stimulating the growth and/or the activity of one or a limited number of
bacteria in the colon that have the potential to improve host health (8, 10). This is based
on the knowledge that the availability of carbohydrates that escape metabolism and
adsorption in the small intestine has a major influence on the microflora that becomes
established in the colon (26). The main prebiotics used are carbohydrates such as resistant
starch, wheat bran, inulin or oligosaccharides (27).

Inulin is a natural component of several fruits and vegetables. It is a mixture of
fructooligosaccharides and fructopolysaccharides (28).

Oligosaccharides are short

polymers of glycosidic residues such as fructose in fructooligosaccharides (FOS) or
galactose in galactooligosaccharides (GOS) (27). FOS is the most commonly used
commercial prebiotic, which is a mixture of oligosaccharides containing a varying
number of fructose moieties connected by β(2→1) glycosidic bonds. GOS originates
from enzymatic transgalactosylation of lactose (10). These soluble and fermentable fibers
cannot be digested by α-amylase or other hydrolases in the upper section of the intestinal
tract and they also resist digestion by gastric acid and pancreatic enzymes (29).

To exert a prebiotic effect, fibers have to be present in foods in amounts of 30-60 mg/g in
solid foods and 15 mg/g in liquid foods (30). The effect will also depend on the actual
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number of beneficial bacteria, such as bifidobacteria, in the host, which has led to
development of products that combine both a probiotic and a prebiotic (28). Prebiotics by
themselves as well as their symbiotic combination with probiotic bacteria have been
shown to increase bifidobacteria and lactobacilli populations and to inhibit various
human and animal pathogenic bacteria in vitro, or in mice, piglets or humans (28). The
addition of prebiotics to products containing probiotics can also protect and stimulate
growth of lactobacilli and bifidobacteria during the product’s shelf life (31, 32).
However, it is important to determine whether the probiotic strain is capable of
metabolizing the prebiotic.

1.4.2. Safety properties of probiotics
There has always been a level of concern about the safe use of lactic acid bacteria as
probiotics. The following safety criteria have been proposed: strains intended for human
use should have a human origin and be isolated from healthy human gastrointestinal tract
and they need to have a non-pathogenic history, not associated with diseases (33). Now,
it is considered necessary to also establish the absence of transmissible antibiotic
resistance genes.

1.4.2.1.

Antibiotic resistance

According to the WHO (34), antimicrobial resistance (AMR) is “the resistance of a
microorganism to an antimicrobial medicine to which it was originally sensitive”. The
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genes that code for resistance are components of natural microbial populations and the
exposure to antibiotics exerts a selective pressure, favoring the microorganisms capable
of surviving (35). Humans encourage the spread of resistant strains by the misuse of
microbial medicines and by poor infection control practices (34).

Awareness of this fact has encouraged major official bodies, such as the European Union
(EU), the Centers for Disease Control and Prevention (CDC) and the WHO, to address
the need of controlling the increase in resistance (36). Most agencies agree that a global
strategy is needed and that it should include comprehensive surveillance of antibiotic
resistant organisms and their associated infections; improved control and monitoring of
antibiotic use in animals and humans; and increased research in the area of resistance
mechanism identification and antibacterial drug product development (34, 37, 38).

Antimicrobial susceptibility testing allows the detection of possible drug resistance in
common pathogens and commensals and to identify the most appropriate drug treatment
for patients (39). Conventional phenotypic methods are based on the assessment of the
growth of bacteria when exposed to the antimicrobial of interest. The results are then
compared to interpretative criteria provided by responsible organizations, such as the
Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for
Clinical Laboratory Standards, or NCCLS) in the United States and the European Union
Committee for Antimicrobial Susceptibility Testing (EUCAST) in Europe (40).The most
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commonly used methods are broth dilution tests, antimicrobial gradient methods and the
disk diffusion test (39).

The known mechanisms of antibiotic resistance can be broadly classified into four
classes: 1) lack or decrease of cell wall permeability, which limits or prevents the intake
of the drug; 2) efflux mechanisms, which allow the bacteria to pump out the antibiotic
from the cell before it reaches an effective concentration; 3) enzymatic deactivation
mechanisms, in which inactivating enzymes alter the antibiotic’s chemical structure to
render it useless; and 4) modification of target mechanisms, in which the target site of the
antibiotic has been altered so it retains its function in the cell but the antibiotic can no
longer bind to it (41). Certain mechanisms, such as lack of cell wall permeability or the
total absence of the target site, are more likely to be inherent to a bacterial species or
genus; therefore this type of resistance is classified as intrinsic or natural (Figure 1.1).
However, strains belonging to a group naturally susceptible to an antibiotic can acquire
resistance through gain of exogenous DNA or by mutation of indigenous genes (42).
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Figure 1.1 Major mechanisms of intrinsic and acquired resistance (42)
(42).

Both intrinsic resistance and acquired resistanc
resistancee by chromosomal mutation have
ha a low
risk of horizontal dissemination between different bacterial species. In contrast, acquired
resistance has a higher potential for transference when the genes are present on mobile
genetic elements, such as plasmids and transposons (43).. Determinants on these mobile
elements
ents move between diverse bacteria and disseminate resistance genes into a variety
of microbial communities (35)

1.4.2.2.

Antibiotic resistance in LAB

Researchers in the last decade have discovered the presence of antibiotic resistance genes
in LAB from different sources. Herreros et al. (44) found multiple drug resistance in
LAB isolated from Armada cheese, a Spanish goat milk cheese. Masco et al. (45)
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discovered tet(W) genes responsible for tetracycline resistance in 15 Bifidobacterium
strains, including 7 probiotic isolates. Surveys of antibiotic resistance phenotypes and
determinants have been conducted with lactic acid bacteria strains of European, African
and Asian origin and resistance genes have been found in all of them (46–49). There is
very little published information about American strains.

However, it is important to distinguish between intrinsic and acquired resistance. For
example, enterococci are intrinsically resistant to cephalosporins and low levels of
aminoglycosides; while lactobacilli, pediococci and Leuconostoc spp. have a high natural
resistance to vancomycin (1). There are both intergenus and interspecies differences.
Danielsen and Wind (50) surveyed 62 strains of Lactobacillus and found that
susceptibility varied several folds between species for drugs such as vancomycin,
tetracycline and clindamycin. These results emphasize the importance of surveillance and
publication of resistance profiles of LAB and other commensal bacteria of industry
interest for the development of safety guidelines for their commercial use.

The European Food Safety Authority (EFSA), for example, took published data about
resistance profiles into account for the development of its safety assessment scheme
(Figure 1.2). This assessment must be done for all strains aiming to be used as additives
in the European Union and represents a complete framework for the characterization of
resistance of any microorganism (42).
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Figure 1.2 EFSA proposed scheme for antimicrobial resistance assessment of a bacterial
strain used as feed or food additive (42).

In this proposed scheme, cut-off values are set by studying the distribution of minimum
inhibitory concentrations (MICs) of the antimicrobials in bacterial populations of the
same species or genus (42). Data about the distribution of MICs is derived from the
published body of research and monitoring programs and may be updated as more
information becomes available (51). Therefore, resistant strains are those for which MICs
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clearly deviate from those of normal susceptible populations. EFSA recognizes nine
antibiotics as antimicrobials of human and veterinary importance; susceptibility to these
substances is considered a basic requirement for bacterial products intended for use as
food and feed additives (Table 1.1) (51).

Table 1.1 Antibiotics recognized as having human and veterinary importance by EFSA
(51).
Mechanism of action

Antibiotic Family

Antibiotics of Importance

Inhibition of cell wall

Penicillins

Ampicillin

synthesis

Glycopeptides

Vancomycin

Inhibition of protein

Aminoglycosides

Gentamycin

synthesis

Kanamycin
Streptomycin
Macrolides

Erythromycin

Lincosamides

Clindamycin

Tetracyclines

Tetracycline

Single antibiotics

Chloramphenicol

The characterization of potentially probiotic strains is a comprehensive process. Beyond
health properties, safety and functionality are also important. The bacteria should be able
to survive processing, storage and digestion conditions. Acid and bile resistance is
essential for its delivery to the small intestine, where it can exert its positive effect.
Prebiotic utilization allows for the formulation of synbiotic products that can protect
bacteria during the product’s shelf life and increase their activity in the intestinal tract.
Most importantly, probiotic strains should be safe for human consumption and inclusion
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in the food chain. The definition of a safe strain has expanded to include the absence of
antibiotic resistance genes, given the alarming increase of resistance in pathogenic and
commensal bacteria worldwide.

Both safety and functional characteristics can be specific to a certain species or a certain
strain of LAB. This makes it necessary to characterize each new strain intended for
probiotic use, especially emerging species like Bacillus coagulans. Therefore, the current
research focused on characterizing the functional and safety properties of ten probiotic
strains, aiming to determine their ability to utilize prebiotics and their antibiotic
resistance. This will contribute to their proper use in the food industry and to the general
knowledge about these species.

•

ObjectivesTo characterize the prebiotic utilization profile of ten probiotic strains in

order to suggest potential synbiotic combinations.
•

To evaluate the antibiotic susceptibility of ten probiotic strains, by both the broth
microdilution and the disk diffusion method, to determine the safety of the strains
and compare the performance of both methods.

•

To determine the in vitro acid and bile tolerance of Bacillus coagulans to predict
its survival in the gastrointestinal tract.
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CHAPTER 2 : MATERIALS AND METHODS
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2.1. Probiotic strains
Ten bacterial strains were obtained from a commercial probiotics supplier (Nebraska
Cultures, Walnut Creek, CA) (Table 2.1). Control strains were purchased from the
American Type Culture Collection (ATCC, Manassas, VA). The freeze-dried cultures
were diluted 1:99 in Phosphate Buffered Saline (PBS; Sigma, St. Louis, MO) and 5 µl
were streaked in appropriate media. Tryptic Soy Agar (TSA, Acumedia, Neogen
Corporation, Lansing, MI) was used for Escherichia coli ATCC 25299 and Streptococcus
pneumoniae ATCC 49619. De Man Rogosa Sharpe agar (MRS, Acumedia, Neogen
Corporation, Lansing, MI) was used for all Lactobacillus, Lactococcus, Bifidobacterium
and Bacillus. Plates were then incubated for 24 hours at 37°C. Plates were incubated
anaerobically with the exception of E. coli ATCC 25922 and S. pneumoniae ATCC
49619. Single colonies were picked and a Gram stain was performed. Colonies with the
expected morphology were grown overnight at 37°C, either in Tryptic Soy Broth (TSB,
Acumedia, Neogen Corporation, Lansing, MI) or MRS broth (Acumedia, Neogen
Corporation, Lansing, MI). Sterile glycerol at 7% (v/v) was added to the cultured broth
and 1-ml aliquots were stored at -80°C. Isolates were then sent for identification by 16s
sequencing (Midi Labs, Newark, DE).
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Table 2.1 Bacterial strains used.
Probiotic strains

Control strains

Lactobacillus acidophilus DDS 1-10

Escherichia coli ATCC 25922

Lactobacillus brevis

Streptococcus pneumoniae ATCC 49619

Lactobacillus delbrueckii subsp. bulgaricus
Lactobacillus casei
Lactobacillus plantarum
Lactobacillus rhamnosus
Lactobacillus salivarius
Lactococcus lactis
Bifidobacterium longum
Bacillus coagulans ProDURA

2.2. Prebiotic utilization by lactic acid bacteria
Probiotic bacterial cultures were prepared by streaking 10 µL of stock culture into MRS
plates and incubating overnight at 37°C. A single colony was then picked and transferred
to 12 mL of MRS broth and incubated overnight at 37°C. For this assay, only
Bifidobacteria were incubated anaerobically, in both plates and tubes.

MRS broth without any sugar (basal MRS) was prepared and autoclaved. Sugar solutions
were prepared, sterilized through a syringe filter (mixed cellulose ester membrane, 0.22
µm pore size, Fisherbrand, Fisher Scientific, Waltham, MA) and added to the sterile
medium to achieve the desired concentration (Table 2.2). Prebiotics used included two
fructooligosaccharide mixtures from different suppliers (FOS, Nutraflora, GTC Nutrition
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Company, Bridgewater, NJ and Orafti P95, Beneo, Manheim, Germany), one
galactooligosaccharide mixture (GOS, Purimune, GTC Nutrition Company, Bridgewater,
NJ), and one inulin mixture (Orafti Synergy 1, Beneo, Manheim, Germany). Since all of
these prebiotics contain residual simple sugars, a background sugar (bg) control was
prepared for each one of them. Glucose was used as a positive control. Glucose and the
prebiotic sugars were added to the media for a final concentration of 1% (w/v).

MRS solutions were dispensed into sterile tubes and inoculated with the bacterial cultures
at a 5% (v/v). Absorbance at 620 nm was read every two hours using a Biomate 3
spectrophotometer (Thermo Scientific, Thermo Fisher Scientific, Waltham, MA). The
corresponding sterile MRS solutions were used as blanks for absorbance measurements.
The aliquot removed for absorbance measurements was diluted with the corresponding
sterile MRS solution when absorbance was higher than 0.500. Growth curves were
prepared from the absorbance measurements. Doubling time during the exponential phase
was determined, as well as the maximal variation of absorbance (Figure 2.1). Doubling
time was defined as the time needed for absorbance to double during the exponential
phase of growth, as observed in the growth curves. Maximal variation of absorbance was
calculated by subtracting the initial absorbance from the highest observed absorbance.
The experiments were performed in triplicate.
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Table 2.2 Sugar and prebiotic concentrations tested.
Treatment

Sugars

Final concentration (%, w/v)

Positive control

Glucose

1.0%

Orafti P95

Mixture of FOS (93%),

0.93% FOS

Fructooligosaccharide

glucose, fructose and

0.0175% glucose

(FOS)

sucrose

0.0175% fructose
0.035% sucrose

Orafti FOS background

Mixture of glucose,

0.0175% glucose

sugars (bg)

fructose and sucrose

0.0175% fructose
0.035% sucrose

Nutraflora FOS

Mixture of FOS (95%),

0.95% FOS

glucose, fructose and

0.0125% glucose

sucrose

0.0125% fructose
0.025% sucrose

Nutraflora FOS bg

Mixture of glucose,

0.0125% glucose

fructose and sucrose

0.0125% fructose
0.025% sucrose

Purimune

Mixture of GOS (93%)

0.93% GOS

Galactooligosaccharide

and lactose

0.07% lactose

GOS bg

Lactose

0.07% lactose

Orafti Sinergy 1 Inulin

Mixture of inulin (92%),

0.92% inulin

glucose, fructose and

0.02% glucose

sucrose

0.02% fructose

(GOS)

0.04% sucrose
Inulin bg

Mixture of glucose,

0.02% glucose

fructose and sucrose

0.02% fructose
0.04% sucrose
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Lactobacillus salivarius

Absorbance at 620 nm
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Figure 2.1 Determination of doubling time (DT) and maximal variation of absorbance
(MVA) from probiotic growth curves.

2.3. Antibiotic resistance
2.3.1. Broth microdilution method for antibiotic resistance
The procedure for broth microdilution was adapted from the CLSI protocol for
antimicrobial susceptibility testing (52). Antibiotic solutions were prepared in LAB
susceptibility media (LSM, 9:1 Isosensitest broth: MRS broth, Oxoid, Acumedia). The
following

antibiotics

were

tested:

ampicillin,

chloramphenicol,

clindamycin,

erythromycin, gentamycin, kanamycin (Sigma Aldrich, St. Louis, MO), oxytetracycline
(Acros Organics, Geel, Belgium), streptomycin (MP Biomedicals, Santa Ana, CA) and
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vancomycin (Fisher Scientific, Waltham, MA). The range of concentrations tested varied
for each antibiotic according to the microbiological breakpoints (bp) defined by EFSA
(51).

Cultures for inoculation were grown overnight by mixing 100 µL of stock culture into 9
mL of MRS broth and incubating anaerobically at 37°C overnight. Control strains were
grown in TSB broth and incubated aerobically. The absorbance of culture tubes was then
adjusted to 0.125-0.132 at 620 nm, the equivalent to a 0.5 McFarland standard (5 x 105
CFU/ml). Absorbance was measured with a Spectronic 20D+ spectrophotometer
(Spectronic Instruments, Thermo Fisher Scientific, Waltham, MA), using MRS broth as a
blank. The antibiotic solutions were used to prepare a 1:200 dilution of bacteria
inoculum.

The mixture of antibiotic solution and inoculum was dispensed into a 96-well plate, with
300 µL per well. Absorbance at 600 nm was measured with iMark Micro Plate Reader
(Bio-Rad, Hercules, CA) at 0, 24 and 48 hours of incubation at 37°C. E. coli and S.
pneumoniae controls were incubated aerobically at 37°C. Growth curves were prepared
so that growth at the breakpoint could be compared with growth of the positive control to
examine susceptibility. For this experiment, it was considered that absorbance of 0.200 or
greater corresponds with growth visible to the naked eye. The experiments were
performed in triplicate.
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2.3.2. Disk diffusion method
The disk diffusion method was a modification of the agar overlay method documented by
Charteris et al. (53). Plates with 15 ml of MRS agar were overlaid with 4 ml of soft agar
containing 200 µL of active culture, prepared as described for the broth microdilution
assays. Antibiotic disks (Becton Dickinson, BD, Franklin Lakes, NJ) with the following
amounts of the active compound were placed into the dry plates: ampicillin (10 µg),
chloramphenicol (30 µg), clindamycin (2 µg), erythromycin (15 µg), gentamycin (10 µg),
kanamycin (30 µg), oxytetracycline (30 µg), streptomycin (10 µg), and vancomycin (30
µg). Plates were then incubated anaerobically at 37°C for 24 h. E. coli and S. pneumoniae
controls were incubated aerobically at 37°C. Inhibition zone diameters were measured
with a colony counter (Flash and Go, IUL Instruments, Neutec Group Inc, Farmingdale,
NY) and interpreted according to the guidelines provided by Charteris et al. (53). Strains
were classified as susceptible or resistant. The experiments were performed in triplicate.

2.4. Acid and bile tolerance of Bacillus coagulans
Freeze-dried spores of Bacillus coagulans (about 2.00 x 1011 CFU/g) were diluted in PBS
to obtain a suspension with 1 x 108 spores/mL. To ensure only spores were present, spore
suspensions were heat treated at 80°C for 12 minutes and then chilled in ice. The method
for acid and bile resistance was modified from Hyronimus et al. (11). Tubes with 10 mL
of MRS broth were adjusted to pH 2.0, 2.5 and 3.0 using 3.0 M hydrochloric acid (Sigma
Aldrich, St. Louis, MO). MRS with 0.3% bile (Sigma Aldrich, St. Louis, MO) was also
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prepared and 10 ml of the broth was dispensed into tubes. MRS broth without addition of
acid or bile salts was used as a control. A 10 µL aliquot of the spore suspension was then
added to each tube. Counts were performed by plating on MRS agar at times 0, 0.5, 1, 2,
and 4h. Plates were incubated aerobically overnight at 37°C. Survival curves were
prepared for each treatment and the area under the curve was compared to the control.
Survival rates were also calculated, as the percent of the initial population that could be
recovered after four hours (log CFU/ml at 4 h divided log CFU/ml at 0 h * 100%). The
experiment was performed in triplicate.

2.5. Statistical analysis
Analysis of variance was used to evaluate the effect of different treatments in the acid
and bile assay and in the prebiotic utilization assay. The analysis was conducted on the
mean doubling time and maximal absorbance variation for the prebiotic growth curves
and for the area under the curve for the acid and bile survival curves, with treatment as
the independent variable. Statistical analysis was carried out using SAS 9.3 (SAS, Inc,
Cary, NC). All tests were conducted at the 5% level of significance.
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CHAPTER 3 : RESULTS AND DISCUSSION
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3.1 Probiotic strain identification
The identity of the probiotic strains was confirmed by 16s sequencing (MidiLabs,
Newark, DE). The reports can be found in Appendix A.

3.2 Prebiotic utilization by lactic acid bacteria
The capacity of nine strains to use prebiotics as a carbon source was evaluated during
growth for 24 hours. Glucose was used as a positive control for growth. The background
sugars in each prebiotic were also evaluated, to establish their effect on growth and rule
out their interference. The mean doubling time during the exponential phase of growth
and the maximal absorbance variation were calculated for each strain and prebiotic. The
results for lactobacilli (Lb.), Lactococcus lactis and Bifidobacterium longum (Bb.
longum) are presented in Table 3.1 and Table 3.2. Figures 3.1 to 3.9 show the average of
three replicates of the experiment for each strain. Results for Bacillus coagulans are
included in its particular section.
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Table 3.1 Mean doubling time of probiotic strains on selected carbohydrates.
Treatment
Glucose
Purimune GOS
Purimune GOS bg2
FOS Orafti
FOS Orafti bg
FOS Nutraflora
FOS Nutraflora bg
Inulin
Inulin bg

Mean Doubling Time (h, average ± standard deviation)1
Lb. acidophilus
Lb. brevis
Lb. casei
1.5 ± 0.4 a
1.4 ± 0.3 a
1.1 ± 0.2 a
1.8 ± 0.7 a
1.7 ± 0.4 a
1.6 ± 0.7 a
2.2 ± 0.9 a
2.0 ± 0.3 a
1.6 ± 0.6 a
1.9 ± 0.6 a
1.6 ± 0.4 a
1.7 ± 0.6 a
1.7 ± 0.5 a
1.7 ± 0.4 a
1.9 ± 0.9 a
1.9 ± 0.5 a
1.9 ± 0.4 a
1.7 ± 0.7 a
2.0 ± 0.3 a
1.9 ± 0.4 a
2.0 ± 1.1 a
1.9 ± 0.4 a
1.8 ± 0.3 a
1.8 ± 0.8 a
1.8 ± 0.3 a
1.8 ± 0.8 a
1.9 ± 0.4 a

Treatment
Glucose
Purimune GOS
Purimune GOS bg
FOS Orafti
FOS Orafti bg
FOS Nutraflora
FOS Nutraflora bg
Inulin
Inulin bg

Lb. delbrueckii
1.6 ± 0.6 a
1.5 ± 1.0 a
1.8 ± 1.4 a
1.8 ± 1.5 a
1.7 ± 1.0 a
1.5 ± 0.8 a
1.6 ± 1.1 a
1.6 ± 1.1 a
1.7 ± 1.1 a

Lb. plantarum
1.5 ± 0.5 a
1.5 ± 0.4 a
2.4 ± 0.6 a,b
3.1 ± 0.8 a,b
3.7 ± 0.8 b
1.8 ± 0.5 a,b
3.5 ± 0.9 a,b
2.8 ± 0.7 a,b
2.9 ± 0.6 a,b

Lb. rhamnosus
1.1 ± 0.2 a
1.6 ± 0.4 a,b
2.9 ± 0.5 a,b,c
3.1 ± 0.4 b,c
4.4 ± 1.0 c
3.4 ± 0.7 b,c
3.2 ± 0.8 b,c
2.4 ± 0.4 a,b
3.1 ± 0.2 a,b,c

Treatment
Lb. salivarius
L. lactis
Bb. longum
2.5 ± 0.7 a
1.9 ± 0.3 a
Glucose
2.2 ± 0.5 a
Purimune GOS
2.4 ± 0.5 a
2.6 ± 0.9 a
3.7 ± 0.6 a,b,c
Purimune GOS bg
4.4 ± 0.7 a,b,c 3.1 ± 1.0 a
3.3 ± 0.8 a,b,c
FOS Orafti
5.6 ± 0.8 c
3.5 ± 0.9 a
2.9 ± 0.6 a,b,c
FOS Orafti bg
5.0 ± 0.9 c
4.4 ± 1.0 a
4.4 ± 0.7 b,c
FOS Nutraflora
2.8 ± 0.6 a,b
4.0 ± 1.1 a
4.5 ± 0.5 c
FOS Nutraflora bg
5.7 ± 0.8 b,c
3.6 ± 1.0 a
2.9 ± 1.0 a,b,c
Inulin
3.8 ± 0.8 a,b,c 3.3 ± 1.0 a
2.0 ± 0.6 a,b
Inulin bg
4.6 ± 1.0 a,b,c 3.4 ± 0.6 a
4.0 ± 0.8 a,b,c
1
Mean doubling times with a different letter are significantly different (p<0.05) from
doubling times for the same strain with other carbohydrates.
2

bg: Background sugars.
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Table 3.2 Maximal absorbance variation of probiotic strains on selected carbohydrates.
Treatment
Glucose
Purimune GOS
Purimune GOS bg2
FOS Orafti
FOS Orafti bg
FOS Nutraflora
FOS Nutraflora bg
Inulin
Inulin bg

Maximal absorbance variation (average ± standard deviation)1
Lb. acidophilus
Lb. brevis
Lb. casei
0.28 ±0.12 a
1.97 ±0.30 a
1.81 ±0.03 a
0.29 ±0.15 a
1.39 ±0.22 a,b
0.67 ±0.02 b
0.28 ±0.13 a
0.94 ±0.09 b
0.43 ±0.06 c
0.21 ±0.03 a
1.06 ±0.13 b
0.34 ±0.09 c
0.27 ±0.16 a
1.02 ±0.08 b
0.33 ±0.08 c
0.28 ±0.12 a
0.98 ±0.21 b
0.30 ±0.08 c
0.21 ±0.07 a
0.96 ±0.07 b
0.23 ±0.05 c
0.31 ±0.18 a
1.17 ±0.16 b
0.31 ±0.07 c
1.16 ±0.05 b
0.33 ±0.09 c
0.28 ±0.17 a

Treatment
Glucose
Purimune GOS
Purimune GOS bg
FOS Orafti
FOS Orafti bg
FOS Nutraflora
FOS Nutraflora bg
Inulin
Inulin bg

Lb. delbrueckii
2.77 ±0.72 a
2.23 ±0.51 a,b
1.56 ±0.26 b
1.28 ±0.19 b
1.31 ±0.22 b
1.69 ±0.37 a,b
1.22 ±0.19 b
1.42 ±0.20 b
1.42 ±0.13 b

Lb. plantarum
1.75 ±0.03 a
1.49 ±0.03 b
0.56 ±0.09 d
0.45 ±0.02 d
0.51 ±0.08 d
0.94 ±0.07 c
0.45 ±0.04 d
0.55 ±0.05 d
0.56 ±0.08 d

Lb. rhamnosus
1.63 ±0.23 a
1.14 ±0.17 b
0.51 ±0.06 c
0.40 ±0.03 c
0.38 ±0.02 c
0.38 ±0.06 c
0.39 ±0.05 c
0.39 ±0.04 c
0.41 ±0.05 c

Treatment
Lb. salivarius
L. lactis
Bb. longum
0.59 ±0.12 a
2.19 ±0.00 a
Glucose
2.15 ±0.25 a
Purimune GOS
1.41 ±0.07 b
0.56 ±0.09 a,b
1.62 ±0.13 b
Purimune GOS bg 0.58 ±0.07 d
0.29 ±0.04 c
0.38 ±0.06 c
FOS Orafti
0.45 ±0.02 d
0.29 ±0.08 c
0.44 ±0.29 c
FOS Orafti bg
0.46 ±0.06 d
0.30 ±0.07 b,c
0.40 ±0.07 c
FOS Nutraflora
1.04 ±0.06 c
0.28 ±0.06 c
0.39 ±0.16 c
FOS Nutraflora bg 0.53 ±0.07 d
0.29 ±0.08 b,c
0.28 ±0.11 c
Inulin
0.65 ±0.09 d
0.30 ±0.08 b,c
0.46 ±0.08 c
Inulin bg
0.54 ±0.02 d
0.31 ±0.07 b,c
0.49 ±0.13 c
1
Maximal absorbance variations with a different letter are significantly different (p<0.05)
from maximal absorbance variations for the same bacteria with other carbohydrates.
2

bg: Background sugars.
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Figure 3.1 Growth of Lactobacillus acidophilus DDS 1-10 on selected carbohydrates.
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Figure 3.2 Growth of Lactobacillus brevis on selected carbohydrates.
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Figure 3.3 Growth of Lactobacillus casei on selected carbohydrates.
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Figure 3.4 Growth of Lactobacillus delbrueckii on selected carbohydrates.
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Figure 3.5 Growth of Lactobacillus plantarum on selected carbohydrates.
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Figure 3.6 Growth of Lactobacillus rhamnosus on selected carbohydrates.
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Figure 3.7 Growth of Lactobacillus salivarius on selected carbohydrates.
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Figure 3.8 Growth of Lactococcus lactis on selected carbohydrates.
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Figure 3.9 Growth of Bifidobacterium longum on selected carbohydrates.

Mean doubling times with glucose ranged from 1.1 ± 0.2 hours for Lb. casei and Lb.
rhamnosus to 2.5 ± 0.7 h for L. lactis. Mean doubling times were generally higher for
glucose than for any other treatment for all bacteria; however, the difference between
glucose and the rest of the treatments was not significant in most of the cases (p>0.05).
This may be due to the high variability between replicates, as shown by the standard
deviation.

There was also no significant difference in doubling time between each prebiotic and its
corresponding background sugars. This suggests that the strains utilized the available
background sugars and residual glucose from inoculum during the beginning of the
exponential phase, which allowed for mean doubling times similar to those of glucose.
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Only after these sugars were exhausted would the strains be expected to begin utilizing
the prebiotics.

With the exception of Lb. acidophilus, all strains showed a higher absorbance increase
for glucose than for the majority of background sugars, as shown in Figures 3.1 through
3.9. This was expected, as glucose is the preferred carbon source for most
microorganisms and similar results have been reported (54, 55). The lack of differences
for Lb. acidophilus may be due to the low levels of growth achieved during the
experiment. It is possible that different results could be obtained when incubating
anaerobically. GOS use by this species has been reported under anaerobic conditions (54,
56).

Based on the maximal absorbance variation (Table 3.2), Purimune GOS was significantly
utilized by Lb. casei, Lb. plantarum, Lb. rhamnosus, Lb. salivarius, L. lactis and Bb.
longum, as the maximal absorbance increase was higher than the one for background
sugars. However, it was not as high as the growth with glucose. Lb. casei showed a slight
growth with GOS, enough to be different from the background sugars. This agrees with
the results of Cardelle-Cobas et al. (56), who reported maximum optical densities of up to
0.6 for Lb. casei with different galactooligosaccharides as the sole carbon source. In their
study, the optical densities obtained with the GOS were similar to those achieved with
lactose, which served as their positive control.
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Lb. plantarum, Lb. rhamnosus, and Lb. salivarius were able to achieve significantly
higher absorbance variations in GOS than in its background sugars. Cardelle-Cobas et al.
(56) reported growth of Lb. plantarum and Lb. salivarius on GOS comparable to that
achieved on lactose, their control sugar. L. lactis showed similar growth on glucose and
GOS, which contrasts with the findings of Gopal et al. (57), who reported that none of 20
Lactococci strains were able to grow on GOS.

Lb. brevis and Lb. delbrueckii were not able to significantly utilize GOS, as there was no
difference between GOS and its background sugars. Several studies have shown that the
ability to ferment prebiotics is strain and substrate specific, due to differences in
metabolic capacity of related strains (56). β-galactosidases are required for degradation of
GOS into glucose and galactose (55). Lactobacilli express only intracellular βgalactosidases and lack transport systems for GOS, which explains their usual preference
for GOS with a low degree of polymerization so they can be internalized by lactose
permeases such as LacS (55, 58). Therefore, utilization of prebiotics requires the
presence of specific hydrolysis and transport systems for each prebiotic and the genes
coding for these systems may not be present in the different strains (54). Genes encoding
for LacS are highly conserved in intestinal lactobacilli, due to their importance for
survival in the gastrointestinal tract (58). It is possible that the Lb. brevis and Lb.
delbrueckii strains used in this study are non-intestinal in origin and therefore lack these
genes.
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Bb. longum was the only bacteria capable of achieving the same level of growth with
GOS as with glucose. The ability of GOS to generate a beneficial shift in the colonic
microbiota towards Bifidobacteria, known as a “bifidogenic effect”, has been widely
reported in the literature (10, 59, 60). GOS was the only prebiotic to support growth of
Bb. longum, as the rest were not significantly different from their corresponding
background sugars. This agrees with previous studies using mixed flora samples, where
the prebiotic index scores for GOS were higher than those for FOS and inulin (54).

Orafti FOS did not promote significant growth of any of the tested strains. This contrasts
with several reports in the literature of satisfactory growth of lactobacilli and
bifidobacteria on this prebiotic (61, 62). However, Nutraflora FOS caused a significant
increase in absorbance for Lb. plantarum and Lb. salivarius. Successful utilization of
Nutraflora FOS by Lb. plantarum strains has been previously reported by Huebner et al.
(54). They also reported differences in the increase in cell densities between lactobacilli
when grown on either Nutraflora P95 FOS or Orafti Raftilose P95 FOS. The difference in
utilization could be due to the higher number of fructose chains with a glucose end unit in
cane sugar-derived Nutraflora FOS than in chicory root-derived Orafti FOS (63).

Inulin did not promote significant growth of any of the strains tested. Inulin is a fructan
of longer chain length than FOS, and non-digestible oligosaccharides of long chain length
are less easily fermented by intestinal microbiota (64). Rossi et al. (65) reported that only
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eight strains from a group of 55 Bifidobacterium strains were able to ferment inulin.
Their strain set included two Bb. longum, from calf and human origin, which were not
able to ferment inulin. The capacity to ferment inulin was linked to the presence of
extracellular β-fructofuranosidase, the enzyme that hydrolyzes FOS and inulin (65). Van
de Wiele et al. (64) also reported it took more time to observe significant effects from
inulin than from FOS in the Simulator of Human Intestinal Microbial Ecosystem
(SHIME). Therefore, it is possible that the strains studied lack the extracellular enzymes
needed to hydrolyze FOS and inulin, or that assay time was not enough to observe the
prebiotic effect of inulin.

3.3 Antibiotic resistance
The susceptibility profiles of ten probiotic strains were evaluated by both the broth
microdilution method and the agar diffusion method. Results for the broth microdilution
assay are presented in Table 3.3. Profiles from the disk diffusion method can be found in
Table 3.4. Table 3.5 summarizes and compares the results for both methods. Of the 82
bacteria-antibiotic combinations tested, 60 were classified as susceptible by both
methods, while the other 12 were classified as resistant by either one or both methods.
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Table 3.3 Antibiotic susceptibility profiles of strains by the broth microdilution method
using EFSA susceptibility breakpoints.
Antibiotic
Ampicillin

Bacteria
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Chloramphenicol Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Clindamycin
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
1
n.r. not required by EFSA

MIC (mg/L)
1-2
2
1
1
1
1
2
1
1
n.r.1
4
4
8
4
8
4
4
2
4
2
0.5
>2
>2
1
1
1
0.5
>1
4
4

Breakpoint (mg/L)
1
2
4
1
2
4
4
2
2
n.r.
4
4
4
4
8
4
4
4
8
8
1
1
1
1
2
1
1
1
1
4

Classification
Variable
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
n.r.
Susceptible
Susceptible
Resistant
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
Resistant
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
Resistant
Susceptible

40

Table 3. 3. Antibiotic susceptibility profiles of strains by the broth microdilution method
using EFSA susceptibility breakpoints (continued).
Antibiotic
Erythromycin

Gentamycin

Kanamycin

Oxytetracycline

Bacteria
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum

MIC (mg/L)
0.5
1
1
2
0.5
0.5
0.5
0.5 - >2
0.5
1
16
16
16
16
16
16
32
16
16
4
64
32
64
16
64
64
>64
n.r.1
16
8
4
8 – 16
4
4
32
8
4
4

Breakpoint (mg/L)
1
1
1
1
1
1
1
1
1
4
16
16
32
16
16
16
16
64
32
4
64
32
64
16
64
64
64
n.r.
64
8
4
8
4
4
32
8
8
8

Classification
Susceptible
Susceptible
Susceptible
Resistant
Susceptible
Susceptible
Susceptible
Variable
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
n.r.
Susceptible
Susceptible
Susceptible
Variable
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
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Table 3. 3. Antibiotic susceptibility profiles of probiotic strains by the broth microdilution
method using EFSA susceptibility breakpoints (continued).
Antibiotic
Oxytetracycline

Bacteria
L. lactis
B. coagulans
Streptomycin
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Vancomycin
Lb. acidophilus
Lb. brevis
Lb. casei
Lb. delbrueckii
Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
1
n.r. not required by EFSA

MIC (mg/L)
8
4
16
16
16
16
n.r.1
32
>64
128
16
8
2
n.r.
n.r.
1
n.r.
n.r.
n.r.
2
4
1

Breakpoint (mg/L)
4
8
16
64
64
16
n.r.
32
64
128
32
8
2
n.r.
n.r.
2
n.r.
n.r.
n.r.
2
4
4

Classification
Resistant
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
n.r.
Susceptible
Resistant
Susceptible
Susceptible
Susceptible
Susceptible
n.r.
n.r.
Susceptible
n.r.
n.r.
n.r.
Susceptible
Susceptible
Susceptible
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Table 3.4 Antibiotic susceptibility profiles of strains by the disk diffusion method using
susceptibility criteria established by Charteris et al.(53)
Antibiotic

Ampicillin

Bacteria

Lb. acidophilus
Lb. brevis
Resistant ≤ 12 mm
Lb. casei
Moderate 13-15 mm
Lb. delbrueckii
Susceptible ≥ 16 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Chloramphenicol
Lb. acidophilus
Lb. brevis
Resistant ≤ 13 mm
Lb. casei
Moderate 14-17 mm
Lb. delbrueckii
Susceptible ≥ 18 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Clindamycin
Lb. acidophilus
Lb. brevis
Resistant ≤ 8 mm
Lb. casei
Moderate 9-11 mm
Lb. delbrueckii
Susceptible ≥ 12 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
1
n.r. not required by EFSA

Inhibition diameter (mm,
average ± standard
deviation)
38 ± 0.2
29 ± 1.4
36 ± 1.3
38 ± 1.2
45 ± 0.7
38 ± 0.6
32 ± 0.7
39 ± 0.4
34 ± 2.4
n.r.1
36 ± 0.0
35 ± 1.8
33 ± 0.7
36 ± 1.3
29 ± 0.5
31 ± 4.0
31 ± 0.2
25 ± 0.4
30 ± 0.4
39 ± 4.1
18 ± 7.0
15 ± 1.5
14 ± 0.8
39 ± 2.0
12 ± 2.4
20 ± 0.0
26 ± 3.6
14 ± 2.1
22 ± 15.1
43 ± 3.5

Classification

Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
n.r.
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
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Table 3.4. Antibiotic susceptibility profiles of strains by the disk diffusion method using
susceptibility criteria established by Charteris et al. (53) (continued).
Antibiotic
Erythromycin

Bacteria
Lb. acidophilus
Lb. brevis
Resistant ≤ 13 mm
Lb. casei
Moderate 14-17 mm
Lb. delbrueckii
Susceptible ≥ 18 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Gentamycin
Lb. acidophilus
Lb. brevis
Resistant ≤ 12 mm
Lb. casei
Moderate - mm
Lb. delbrueckii
Susceptible ≥ 13 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Kanamycin
Lb. acidophilus
Lb. brevis
Resistant ≤ 13 mm
Lb. casei
Moderate 14-17 mm
Lb. delbrueckii
Susceptible ≥ 18 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
1
n.r. not required by EFSA

Inhibition diameter (mm)
40 ± 1.2
35 ± 1.3
40 ± 0.4
39 ± 1.7
29 ± 1.2
40 ± 0.2
30 ± 0.2
39 ± 0.0
32 ± 1.1
44 ± 4.1
14 ± 0.3
16 ± 0.0
15 ± 0.7
19 ± 1.4
16 ± 0.6
16 ± 0.9
9 ± 0.6
16 ± 0.1
20 ± 0.3
31 ± 0.0
7 ± 0.0
7 ± 0.0
7 ± 0.0
22 ± 0.7
7 ± 0.0
10 ± 0.6
7 ± 0.0
n.r.1
7 ± 0.0
30 ± 0.4

Classification
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
Susceptible
Susceptible
Susceptible
Resistant
Resistant
Resistant
Susceptible
Resistant
Resistant
Resistant
n.r.
Resistant
Susceptible

44

Table 3.4. Antibiotic susceptibility profiles of strains by the disk diffusion method using
susceptibility criteria established by Charteris et al. (53) (continued).
Antibiotic
Tetracycline

Bacteria
Lb. acidophilus
Lb. brevis
Resistant ≤ 14 mm
Lb. casei
Moderate 15-18 mm
Lb. delbrueckii
Susceptible ≥ 19 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Streptomycin
Lb. acidophilus
Lb. brevis
Resistant ≤ 11 mm
Lb. casei
Moderate 12-14 mm
Lb. delbrueckii
Susceptible ≥ 15 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
Vancomycin
Lb. acidophilus
Lb. brevis
Resistant ≤ 14 mm
Lb. casei
Moderate 15-16 mm
Lb. delbrueckii
Susceptible ≥ 17 mm Lb. plantarum
Lb. rhamnosus
Lb. salivarius
Bb. longum
L. lactis
B. coagulans
1
n.r. not required by EFSA

Inhibition diameter (mm)
43 ± 0.9
28 ± 0.1
39 ± 2.3
37 ± 0.6
23 ± 0.2
28 ± 1.9
24 ± 0.1
30 ± 0.2
33 ± 0.2
54 ± 4.8
18 ± 0.3
7 ± 0.1
10 ± 0.1
22 ± 0.3
n.r.
12 ± 0.5
7 ± 0.0
13 ± 0.8
19 ± 1.0
29 ± 1.2
27 ± 0.4
n.r.1
n.r.
28 ± 1.0
n.r.
n.r.
n.r.
7 ± 0.0
23 ± 0.2
42 ± 4.6

Classification
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Resistant
Resistant
Susceptible
n.r.
Moderate
Resistant
Moderate
Susceptible
Susceptible
Susceptible
n.r.
n.r.
Susceptible
n.r.
n.r.
n.r.
Resistant
Susceptible
Susceptible

Table 3.5 Comparison of antibiotic susceptibility profiles of probiotic strains by the broth
microdilution method and disk diffusion method.
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Vancomycin

Streptomycin

Oxytetracycline

Kanamycin

Gentamycin

Erythromycin

Clindamycin

Chloramphenicol

Ampicillin

Susceptibility (Broth microdilution / Disk diffusion)

Bacteria
Lb. acidophilus
V/S S/S S/S S/S S/S S/R S/S S/S S/S
Lb. brevis
S/S S/S R/S S/S S/S S/R V/S S/R
n.r.
Lb. casei
S/S R/S R/S S/S S/S S/R S/S S/R
n.r.
Lb. delbrueckii
S/S S/S S/S R/S S/S
S/S S/S S/S S/S
Lb. plantarum
S/S S/S S/S S/S S/S S/R S/S
n.r.
n.r.
Lb. rhamnosus
S / S S / S S / S S / S S / S S / R S / S S/MS n.r.
Lb. salivarius
S/S S/S S/S S/S R/R R/R S/S R/R
n.r.
n.r.
S / S S/MS S / R
Bb. longum
S/S S/S R/S V/S S/S
L. lactis
S/S S/S R/S S/S S/S S/R R/S S/S S/S
B. coagulans
n.r.
S/S S/S S/S S/S
S/S S/S S/S S/S
R: Resistant, S: Susceptible, MS: Moderately Susceptible, V: Variable, N.R.: Not
required.

3.2.1

Lactobacilli strains

Lactobacillus acidophilus was susceptible to all antibiotics by the broth microdilution
method. However, it was classified as resistant to kanamycin by the disk diffusion
method. Several studies have found that intrinsic resistance to kanamycin in the
Lactobacillus acidophilus group is higher than initially described (50, 66). For example,
Danielsen and Wind (50) suggested a breakpoint of >256 mg/L for kanamycin for all
Lactobacillus species after testing 37 strains. The new distribution data prompted the
European Food Safety Authority (EFSA) to change their regulatory limits accordingly,
increasing the resistance breakpoint for this species from 16 mg/L in 2008 to 64 mg/L in
2012 (42, 51). The MICs found for all antibiotics were comparable to those reported by
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Mayrhofer et al. (66), who characterized the susceptibility of 101 strains belonging to the
Lb. acidophilus group, including 10 strains of Lb. acidophilus.

Lactobacillus

plantarum,

Lactobacillus

rhamnosus,

Lactobacillus

brevis

and

Lactobacillus casei were also classified as resistant to kanamycin solely by the disk
diffusion assay. The MIC for kanamycin for all strains coincided with the EFSA
breakpoint. This suggests that the limits for the disk diffusion test might need to be
reviewed for this antibiotic when testing Lactobacillus species. The cut-off values for the
disk diffusion method were proposed by Charteris et al. in 1998 (53) and have been used
in several studies since then (67–69). Mayrhofer et al. (70) recently compared the broth
microdilution and agar disk diffusion methods for susceptibility testing of Lb. acidophilus
group members, finding a strong correlation between MICs and inhibition zone diameters
for several antibiotics. However, they did not establish guidelines for classification and
their study did not include kanamycin.

Lb. brevis and Lb. casei both had a similar susceptibility profile, as they were classified
as resistant to streptomycin only by disk diffusion and as resistant to clindamycin only by
broth microdilution. Lb. casei also exhibited resistance to chloramphenicol in the broth
microdilution assay, while Lb. brevis showed variable susceptibility to tetracycline. Both
organisms showed no inhibition zones in the disk diffusion assay for streptomycin; yet,
their MIC was much lower than the EFSA breakpoint (16 mg/L vs 64 mg/L).
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Streptomycin belongs to the aminoglycoside category of antibiotics, which also includes
kanamycin. Increased MICs for aminoglycosides have been reported when using MRS
agar for testing. MRS agar has a lower pH (6.2 ± 0.2) than the pH optimum for this group
of antibiotics (pH 7.8) (71).

Lb. casei or Lb. brevis resistance to clindamycin is rare in the available literature, only
reported for one Lb. casei strain by Charteris et al. (53) and two Lb. brevis strains by
Delgado et al. (72) and Herreros et al. (44). For chloramphenicol, D’Aimmo et al. (33)
reported a MIC of 16 mg/L for 6 strains of Lb. casei, which is higher than the MIC found
in this study (8 mg/L) and the EFSA breakpoint (4 mg/L). Resistance has also been
reported for 10 out of 29 Lb. casei isolates from European probiotic products examined
by the disk diffusion assay (73). Resistance to chloramphenicol, clindamycin or
tetracycline is not intrinsic to lactobacilli; therefore, it would be important to study for the
presence of known genes providing such resistance in these strains.

Lactobacillus delbrueckii subsp. bulgaricus only showed resistance to erythromycin in
the broth microdilution assay. It was classified as susceptible to all other antibiotics. The
erythromycin resistance determinant erm(B) has been reported previously in different
lactobacilli from different sources (46, 74–76). As an acquired resistance determinant, it
can be potentially be transferred to other bacterial species, as shown by Nawaz et al. (76).
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This raises a concern regarding the safety of this strain, making it necessary to screen for
the presence of this resistance determinant.

In contrast, Lactobacillus salivarius was the only strain to show clear resistance to more
than one antibiotic in both assays. It was not susceptible to the three aminoglycosides:
gentamycin, kanamycin and streptomycin. The MIC for kanamycin was >64 mg/L, the
highest concentration tested. However, as discussed with Lb. acidophilus, Danielsen and
Wind (50) have suggested a breakpoint of >256 mg/L for kanamycin for all Lactobacillus
species after testing 37 strains. The MIC for streptomycin for L. salivarius was also >64
mg/L, while the MIC for gentamycin was 32 mg/L. This is in agreement with previous
reports of a lower MIC for gentamycin than for the rest of the aminoglycosides (50). The
three aminoglycoside antibiotics act as inhibitors of protein synthesis (53). Lactobacilli
show intrinsic resistance to this group of antibiotics due to cell wall structure and
membrane impermeability, which may be complemented by efflux mechanisms (49).
However, the presence of resistance determinants such as aac(6’)-aph(2’’) for gentamicin
and kanamycin resistance and ant(6) and aphE for streptomycin resistance, has been
reported in Lb. plantarum (49) and Bifidobacterium longum (75). Multidrug resistance is
not common in lactobacilli, so presence of acquired resistance genes cannot be ruled out.
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3.2.2

Other probiotic strains

Lactococcus lactis was resistant to kanamycin (inhibition zone diameter = 7 mm) in the
disk diffusion assay. This could be due to media interference, as previously discussed.
Lactococci also have a high natural resistance to gentamicin and kanamycin (2).
Additionally, it was classified as resistant to clindamycin (MIC = 4 mg/L) and
oxytetracycline (MIC = 8 mg/L) by the broth microdilution method. Ammor et al. (75)
characterized the MICs of 50 L. lactis strains for 6 antibiotics, including clindamycin and
tetracycline. The MICs ranged from <0.032 to 0.5 mg/L for clindamycin and from 0.125
to 0.5 mg/L for tetracycline. The incidence of resistance to antibiotics in lactococci is low
in the literature; however, Rodriguez-Alonso et al. (77) did find lactococci strains
resistant to tetracycline (n = 2) and clindamycin (n =1) during their survey of 46
lactococci isolates from artisanal raw milk cheeses. As broth microdilution is considered
the standard method for determining antibiotic resistance, it is recommended to look for
genetic determinants for the observed resistance in this strain.

The only Bifidobacterium in the group, Bb. longum, exhibited a variable profile, with
many differences among methods. It showed certain resistance to clindamycin and
erythromycin in the broth microdilution assay and resistance to streptomycin and
vancomycin in the disk diffusion method. Erythromycin is a member of the macrolide
family of antibiotics, while clindamycin is part of the lincosamides. Resistance to both
antibiotics in the same strain suggests a common resistance mechanism, which leads to
the phenotype known as macrolide-lincosamide-streptogramin (MLS) phenotype (75).
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This phenotype is due to the presence of erm genes encoding a 23S rRNA methylase that
modifies the antibiotic’s target (78). Several classes of erm genes have been reported in a
number of clinically important organisms, as well as in several lactic acid bacteria (73).

Some bifidobacteria species are considered naturally resistant to aminoglycosides (2),
which explains the lack of a MIC for kanamycin amongst the EFSA guidelines.
Vancomycin resistant bifidobacteria were found by Charteris et al. (79) when using the
disk diffusion method. However, most reports classify bifidobacteria species as
susceptible to this antibiotic (2, 72). The discrepancy may be due to differences in assay
methodology, since it has been suggested that vancomycin diffuses poorly in agar (79).
Lastly, the variability observed for Bb. longum could be explained by the use of methods
optimized for lactobacilli, which leads to occasional poor growth and low repeatability of
results.

3.2.3

Comparison of broth microdilution and disk diffusion methods

The broth microdilution and disk diffusion methods were in agreement for 76.8% (63/82)
of the bacteria-antibiotic combinations tested, as shown in Table 3.6. Both methods found
similar numbers of resistant and susceptible bacteria. However, each method seems to
have a slight bias. The broth microdilution classified four more bacteria as resistant to
clindamycin than the disk diffusion method. The disk diffusion method classified six
more bacteria as resistant to kanamycin than the broth microdilution method (Table 3.5).
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Table 3.6 Comparison of broth microdilution and disk diffusion methods for bacteriaantibiotic combinations tested.
Method
Broth microdilution
Disk diffusion
Both methods

Resistant
10
12
3

Susceptible
69
68
60

Variable or Moderate
3
2
19

Total
82
82
82

As for precision of the methods, Mayrhofer et al. (70) suggests an acceptable
repeatability of ±1 log base 2 for MICs and ± 3 to 4 mm for inhibition zone diameters for
disk diffusion. All MICs determined were within this suggested range, while 5 inhibition
zone diameters had a standard deviation higher than 4 millimeters. Interestingly, 3 of
those diameters were related to Bacillus coagulans. This may be explained by the
optimization of the disk diffusion method for lactobacilli species. The antibiotics with
larger standard deviations for inhibition zone diameters were clindamycin (average
standard deviation: 2.5 mm), erythromycin (average standard deviation 1.5 mm) and
chloramphenicol (average standard deviation: 1.4 mm). This confirms the acceptable
repeatability of the disk diffusion method, as well as the broth microdilution method.

3.3 Properties of the potential probiotic strain Bacillus coagulans ProDura

3.3.1

Acid and bile tolerance of Bacillus coagulans

The in vitro tolerance of Bacillus coagulans to either acid or bile was assessed during a
period of four hours. The average counts (log CFU/g) for each treatment are presented in
Figure 3.10. Survival was compared against the control using the area under the curve
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and survival rates (Table 3.7). Bacillus coagulans spores were able to survive all
conditions tested, including pH 2.0. Survival ranged from 72.5 ± 3.3% in pH 2.0 to 91.9
± 3.6% in 0.3% bile salts. Acidic conditions had a significant effect over survival,
decreasing counts by at least 1 log cycle for all the pH values tested. As expected,
reductions in counts were higher at the lower pH values.

7.5

7.0

LOG CFU/ml

6.5

6.0

Control
pH 2.0
pH 2.5

5.5

pH 3.0
Bile

5.0

4.5

4.0
0

1

2

3

4

5

Time (h)

Figure 3.10 Bacillus coagulans cell survival in MRS broth with either acid or bile salts.
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Table 3.7 Bacillus coagulans tolerance to acid and bile salts.
Average area under the curve

Average survival

(log CFU/ml * h, ± SD)1

(% , ± SD)

Control

27.42 ± 0.30 a

99.5 ± 3.0 a

pH 2.0

21.34 ± 0.90 c

72.5 ± 3.3 d

pH 2.5

22.59 ± 0.56 b,c

79.4 ± 1.5 c,d

pH 3.0

24.60 ± 1.31 b

86.6 ± 5.3 b,c

Bile salts (0.3%)

26.72 ± 0.09 a

91.9 ± 3.6 a,b

Treatment

1

Treatments with different letters within the same column are significantly different
(p<0.05).

Bacillus coagulans survival in low pH has been documented before. Sudha et al. (80)
found a 2 log cycle reduction in B. coagulans Unique IS-2 spore counts after exposing
the strain to pH 1.5 for 3 hours and a 1 log cycle reduction at pH 2.0 and 3.0. The strain
studied here exhibited greater susceptibility to pH 2.0, with a predicted 2 log cycle
reduction after 3 hours. Tolerance seems to vary amongst strains of B. coagulans, as
Hyronimus et al. (11) tested 3 different strains (BCI4 LMAB, CIP5264 and CIP6625) and
none of them showed detectable survival after 3 hours at pH 2.5. Those three strains were
also weakly tolerant to 0.3% bile. B. coagulans Unique IS-2, on the other hand, had only
a 1 log cycle reduction after 3 hours in 1.0% bile (80). Maathuis et al. (14) tested survival
of B. coagulans GanedenBC30 during passage through a dynamic model of the stomach
and small intestine (TIM-1) and found high survival (70%).
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In vitro tolerance to acid and bile has been positively correlated to survival in both human
and pig gastrointestinal tracts (81, 82). Guo et al. (81) screened Bacillus strains for
probiotic characteristics, including acid and bile tolerance. B. subtilis MA 139 had
constant counts during 3 hours at pH 2.0 and was capable of growing in mixed nutrient
broth with 0.3% bile. It was also able to exert a probiotic effect in pigs. Succi et al. (83)
found that the popular probiotic strain, Lactobacillus rhamnosus GG, showed reductions
of 2 log cycles and 6 log cycles when exposed for 2 hours to pH 3.0 and pH 2.0,
respectively. Survival in the gut is supposed to be higher thanks to the buffering effect of
food products consumed at the same time as the probiotic. Bacillus coagulans strains
show higher tolerance to acid than L. rhamnosus GG, so that their delivery to the lower
intestinal tract is very promising. Their tolerance to acid would also make them suitable
for addition to acidified foods, where they could arguably survive and remain viable.

3.3.2

Prebiotic utilization by Bacillus coagulans

The capacity of B. coagulans to use four commercial prebiotics as a carbon source was
evaluated during growth for 24 hours. Glucose was used as a positive control for growth.
The background sugars in each prebiotic were also evaluated, to establish their effect on
growth and rule out their interference. The mean doubling time during the exponential
phase of growth and the maximal absorbance variation were calculated for each prebiotic.
Results are presented in Table 3.8 and Figure 3.11.
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Mean doubling times ranged from 1.2 to 2.0 hours, but were not significantly different
amongst all treatments. Based on maximal absorbance variation, B. coagulans grew well
on media supplemented with glucose, as expected. It showed similar growth on media
supplemented with GOS. Maximal absorbance variation was significantly higher for
glucose and GOS, doubling the absorbance obtained with other treatments. It must be
noted that the maximal absorbance variation (0.57 ± 0.02) is much lower than those
observed with the other probiotic strains tested. This suggests that, while B. coagulans is
capable of growing in the test conditions, these are not optimal for growth.

Table 3.8 Prebiotic utilization by Bacillus coagulans.
Mean doubling time (h,
Maximal absorbance variation
Treatment
average ± standard deviation)1 (average ± standard deviation)2
Glucose
1.2
± 0.0
a
0.57
± 0.02
a
Purimune GOS
1.4
± 0.1
a
0.50
± 0.07
a
3
Purimune GOS bg
1.7
± 0.3
a
0.23
± 0.05
b
FOS Orafti
1.8
± 0.3
a
0.14
± 0.03
b
FOS Orafti bg
1.8
± 0.6
a
0.17
± 0.06
b
FOS Nutraflora
2.0
± 0.6
a
0.16
± 0.03
b
FOS Nutraflora bg
1.7
± 0.4
a
0.19
± 0.04
b
Inulin
1.4
± 0.4
a
0.19
± 0.03
b
Inulin bg
1.9
± 0.5
a
0.19
± 0.07
b
1
Mean doubling times with a different letter are significantly different (p<0.05) from
doubling times with other carbohydrates.
2

Maximal absorbance variations with a different letter are significantly different (p<0.05)
from maximal absorbance variations with other carbohydrates.
3

bg: Background sugars.
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Figure 3.11 Growth of Bacillus coagulans on selected carbohydrates.

There is little available information in the literature about in vitro use of prebiotics by B.
coagulans or other Bacillus species. β-galactosidases from Bacillus circulans, B.
coagulans and B. stearothermophilus have been widely studied for the production of
GOS, since β-galactosidases are capable of catalyzing both the hydrolysis of βgalactoside linkages of lactose to glucose and the transgalactosidation reaction to produce
galactooligosaccharides (84–86). It has been reported that Bifidobacterium show greater
growth on GOS produced by their own β-galactosidase than on commercial products
(87). A similar behavior could be expected from Bacillus species and GOS.

Based on the results, no difference in growth between FOS and its background sugars
was found. However, there are several in vivo studies in different species of fish where
feed supplementation with both Bacillus spp. and FOS has resulted in better growth
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performance, survival and non-specific immune response when compared to each
supplement by itself or to a control diet (88–90). This suggests a synbiotic relationship
between the bacteria and the carbohydrate.

B. coagulans was not able to ferment inulin as a carbohydrate source. This agrees with
the results of De Clerck et al. (91) who performed the biochemical characterizations of
31 strains of B. coagulans using the API tests, and found that none of them was capable
of producing acid from inulin.

3.3.3

Antibiotic susceptibility of Bacillus coagulans

Antibiotic susceptibility of B. coagulans was determined by the broth microdilution
method. Results are summarized in Table 3.9.

Table 3.9 Antibiotic susceptibility profile of Bacillus coagulans by broth microdilution
method using EFSA susceptibility criteria.
Antibiotic
Ampicillin
Chloramphenicol
Clindamycin
Erythromycin
Gentamycin
Kanamycin
Oxytetracycline
Streptomycin
Vancomycin
1 n.r. not required

MIC (mg/L)
n.r.1
2
4
1
4
8
4
8
1

Breakpoint (mg/L)
n.r.
8
4
4
4
8
8
8
4

Classification
n.r.
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
Susceptible
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The strain was susceptible to all antibiotics tested, as the minimum inhibitory
concentrations were lower or the same as the EFSA breakpoint. Since interest in B.
coagulans and other Bacillus species as probiotics is fairly recent, there is little available
published information on antibiotic susceptibility profiles. Sorokulova et al. (92) studied
a B. subtilis and a B. licheniformis strain for antibiotic resistance; while the former was
sensitive to all antibiotics listed by EFSA the latter was resistant to chloramphenicol and
clindamycin. Hong et al. (93) found no antibiotic resistance in a B. subtilis strain and
clindamycin resistance in a B. indicus strain. Clindamycin resistance appears to be a
concern in probiotic Bacillus strains. The strain studied here, however, shows no
resistance and can be classified as safe for use as a probiotic.
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4.1 Conclusions
•

The prebiotic utilization profile of ten probiotic strains was determined.
o Lactobacillus acidophilus, Lb. brevis and Lb. delbrueckii subsp.
bulgaricus were unable to ferment any of the four prebiotics tested.
o Orafti P95 FOS and Orafti Synergy 1 inulin did not support growth of any
of the strains tested.
o Purimune galactooligosaccharide (GOS) was fermented by Lb. casei, Lb.
plantarum,

Lb.

rhamnosus,

Lb.

salivarius,

Lactococcus

lactis,

Bifidobacterium longum and Bacillus coagulans.
o Nutraflora P95 fructooligosaccharide (FOS) was fermented by Lb.
plantarum and Lb. salivarius. These prebiotic-probiotic combinations
could be used for a synbiotic formulation.
•

The susceptibility of ten probiotic strains to nine antibiotics was evaluated by two
methods.
o Only Lb. salivarius showed resistance to three antibiotics: gentamycin,
kanamycin and streptomycin; and should not be considered safe for
probiotic use.
o The antibiotic susceptibility profiles obtained by the broth microdilution
method and the disk diffusion method were in agreement for 76.8%
(63/82) of the possible strain-antibiotic combinations, which is considered
satisfactory. They also had acceptable repeatability.
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•

B. coagulans was able to survive acid and bile conditions in vitro for up to 4
hours with a 1.0 log reduction in bile salts and a 2.0 log reduction in pH 2.0. This
predicts survival of the passage through the intestinal tract and success as a
probiotic.

4.2 Future Research
Areas of interest to continue with this research include:
•

In vivo evaluation of prebiotic utilization by the probiotic strains and possible
synbiotic effects.

•

Anaerobic evaluation of prebiotic utilization by Lactobacillus acidophilus.

•

Determination of resistance determinants in Lactobacillus salivarius and strains
found to be resistant in just one of the two methods tested.

•

Examination of a larger set of strains by both microdilution and disk diffusion
methods in order to establish updated evaluation criteria for the disk diffusion
method.

•

Determination of acid and bile resistance of B. coagulans in vivo or in vitro by a
more complex model.
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